192 related articles for article (PubMed ID: 20498617)
1. Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels.
Clerc RG; Stauffer A; Weibel F; Hainaut E; Perez A; Hoflack JC; Bénardeau A; Pflieger P; Garriz JM; Funder JW; Capponi AM; Niesor EJ
J Hypertens; 2010 Aug; 28(8):1676-86. PubMed ID: 20498617
[TBL] [Abstract][Full Text] [Related]
2. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition.
Hu X; Dietz JD; Xia C; Knight DR; Loging WT; Smith AH; Yuan H; Perry DA; Keiser J
Endocrinology; 2009 May; 150(5):2211-9. PubMed ID: 19164467
[TBL] [Abstract][Full Text] [Related]
3. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
Akizuki O; Inayoshi A; Kitayama T; Yao K; Shirakura S; Sasaki K; Kusaka H; Matsubara M
Eur J Pharmacol; 2008 Apr; 584(2-3):424-34. PubMed ID: 18331727
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of dalcetrapib.
Stein EA; Stroes ES; Steiner G; Buckley BM; Capponi AM; Burgess T; Niesor EJ; Kallend D; Kastelein JJ
Am J Cardiol; 2009 Jul; 104(1):82-91. PubMed ID: 19576325
[TBL] [Abstract][Full Text] [Related]
5. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.
Blasi E; Bamberger M; Knight D; Engwall M; Wolk R; Winter S; Betts A; John-Baptiste A; Keiser J
J Cardiovasc Pharmacol; 2009 Jun; 53(6):507-16. PubMed ID: 19455053
[TBL] [Abstract][Full Text] [Related]
6. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
Vergeer M; Bots ML; van Leuven SI; Basart DC; Sijbrands EJ; Evans GW; Grobbee DE; Visseren FL; Stalenhoef AF; Stroes ES; Kastelein JJ
Circulation; 2008 Dec; 118(24):2515-22. PubMed ID: 19029469
[TBL] [Abstract][Full Text] [Related]
7. Expression of N-type calcium channels in human adrenocortical cells and their contribution to corticosteroid synthesis.
Aritomi S; Wagatsuma H; Numata T; Uriu Y; Nogi Y; Mitsui A; Konda T; Mori Y; Yoshimura M
Hypertens Res; 2011 Feb; 34(2):193-201. PubMed ID: 20981032
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X
Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613
[TBL] [Abstract][Full Text] [Related]
9. Torcetrapib impairs endothelial function in hypertension.
Simic B; Hermann M; Shaw SG; Bigler L; Stalder U; Dörries C; Besler C; Lüscher TF; Ruschitzka F
Eur Heart J; 2012 Jul; 33(13):1615-24. PubMed ID: 21920972
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II type 1 receptor activation modulates L- and T-type calcium channel activity through distinct mechanisms in bovine adrenal glomerulosa cells.
Maturana AD; Burnay MM; Capponi AM; Vallotton MB; Rossier MF
J Recept Signal Transduct Res; 1999; 19(1-4):509-20. PubMed ID: 10071781
[TBL] [Abstract][Full Text] [Related]
11. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats.
Stroes ES; Kastelein JJ; Bénardeau A; Kuhlmann O; Blum D; Campos LA; Clerc RG; Niesor EJ
Br J Pharmacol; 2009 Dec; 158(7):1763-70. PubMed ID: 19917065
[TBL] [Abstract][Full Text] [Related]
12. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
Shinkai H
Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
[TBL] [Abstract][Full Text] [Related]
13. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.
Vergeer M; Stroes ES
Am J Cardiol; 2009 Nov; 104(10 Suppl):32E-8E. PubMed ID: 19895942
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin I modulates Ca-transport systems in the rat heart through angiotensin II.
Krizanova O; Orlicky J; Masanova C; Juhaszova M; Hudecova S
J Mol Cell Cardiol; 1997 Jun; 29(6):1739-46. PubMed ID: 9220359
[TBL] [Abstract][Full Text] [Related]
15. Dalcetrapib: a review of Phase II data.
Robinson JG
Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
[TBL] [Abstract][Full Text] [Related]
16. Regulation of vascular L-type Ca2+ channels by phosphatidylinositol 3,4,5-trisphosphate.
Le Blanc C; Mironneau C; Barbot C; Henaff M; Bondeva T; Wetzker R; Macrez N
Circ Res; 2004 Aug; 95(3):300-7. PubMed ID: 15242973
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on HDL-raising therapies: insights from the torcetrapib trials.
Kontush A; Guérin M; Chapman MJ
Nat Clin Pract Cardiovasc Med; 2008 Jun; 5(6):329-36. PubMed ID: 18431367
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II increases expression of alpha1C subunit of L-type calcium channel through a reactive oxygen species and cAMP response element-binding protein-dependent pathway in HL-1 myocytes.
Tsai CT; Wang DL; Chen WP; Hwang JJ; Hsieh CS; Hsu KL; Tseng CD; Lai LP; Tseng YZ; Chiang FT; Lin JL
Circ Res; 2007 May; 100(10):1476-85. PubMed ID: 17463319
[TBL] [Abstract][Full Text] [Related]
19. Increased migration of vascular adventitial fibroblasts from spontaneously hypertensive rats.
Li L; Zhu DL; Shen WL; Gao PJ
Hypertens Res; 2006 Feb; 29(2):95-103. PubMed ID: 16755143
[TBL] [Abstract][Full Text] [Related]
20. Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition.
Connelly MA; Parry TJ; Giardino EC; Huang Z; Cheung WM; Chen C; Cools F; Van der Linde H; Gallacher DJ; Kuo GH; Sarich TC; Demarest KT; Damiano BP
J Cardiovasc Pharmacol; 2010 May; 55(5):459-68. PubMed ID: 20051879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
